Joe Rogan Experience #2469 - Brigham Buhler

The current FDA administration, under Secretary Kennedy and Marty McCary, is actively working to reclassify peptides, moving away from the previous administration's 'dangerous' designation. This shift is driven by leadership that personally uses and understands peptides, and a recognition of the lack of safety data supporting the ban. This administration has already moved to remove blackbox warnings on testosterone and hormone replacement therapy (HRT), acknowledging that decades of fear-mongering around these treatments were based on flawed science and dogma.

Brigham Buhler states, 'the administration is still working diligently to reclassify peptides... I'm truly the most optimistic I've ever been and with reason.' He notes the FDA consensus under new leadership to remove blackbox warnings on hormones, stating, 'all the you're being told on testosterone and HRT and hormones, men and women, is wrong. It's dogma. It's been debunked.'

The widespread concern linking testosterone therapy to prostate cancer originates from a single, highly flawed study conducted in the 1930s involving only three patients. Modern research, including studies from the 1990s and retrospective analysis of millions of men on testosterone therapy, has found no correlation between testosterone therapy and increased risk of prostate cancer. Optimal testosterone levels may even provide insulatory benefits against certain cancers.

Buhler explains, 'all of the fear with prostate cancer literally comes from a study from the 1930s... there were three patients in the study.' He adds, 'all of the studies henceforth have shown there is not one single study that correlates testosterone therapy to prostate cancer.'

Pharmaceutical giants exert immense lobbying power to protect their patents and market share, particularly evident in the conflict over GLP-1 weight loss drugs. They accuse compounding pharmacies of patent infringement, despite often developing drugs from taxpayer-funded NIH research and then monetizing them. The FDA's request for compounders to produce GLP-1s during shortages was later met with pharma-driven backlash, leading to restrictions on compounders, even as pharma companies like Eli Lilly acquired Chinese peptide companies.

Buhler states, 'the lobbying power of big pharma is real. It's real and it's intense.' He details how the FDA sent a 'bat signal' for compounders to make GLP-1s during shortages, then pharma companies complained, even though 'Eli Lilly 7xed the value of their company, they're worth $800 billion.' He also points out, 'Eli Lilly just signed a $7 billion deal to acquire a peptide company out of China.'

Muse (Multi-lineage, Stress-Enduring) stem cells, discovered by Mari Dazawa in 2010, represent a significant breakthrough in regenerative medicine. These rare, ultra-resilient cells are naturally occurring, non-tumorigenic, immunomodulatory (meaning the body doesn't reject them), and pluripotent, capable of differentiating into any damaged cell type. They exhibit superior 'honing' abilities, effectively targeting and regenerating damaged tissues, with studies showing remarkable results in brain function recovery and mitochondrial age reduction.

Buhler recounts Mari Dazawa's discovery and states, 'these muse stem cells are such a rare subset phenotype of stem cell... they can become anything.' He mentions, 'in studies, these cells had no never became tumors... in many of the studies, the tumors shrunk.' He highlights their '15 to 30% engraftment rate' and ability to 'pass the lungs and make it to the site of inflammation and damage.'

Gene sequencing offers a powerful tool for predictive and personalized medicine, revealing an individual's genetic predispositions to certain health issues or strengths. By understanding one's 'software' (genes), lifestyle and treatment plans can be tailored to mitigate risks or leverage inherent advantages. This goes beyond traditional blood work, providing a foundational blueprint for long-term health optimization.

Buhler explains, 'your genes are the software that are telling the computer how to run.' He uses Gordon Ryan as an example, whose gene sequencing revealed a 'one in 10 million' gene for dense tendons and bones, alongside a predisposition to staff infections and an acidic gut, allowing for targeted health strategies.